Phlox Therapeutics

Phlox Therapeutics is a biotechnology company developing first-class RNA therapies for cardiomyopathy. The lead project of Phlox Therapeutics primarily targets laminopathy, a rare hereditary cardiomyopathy that can cause various symptoms affecting the heart and skeletal muscles. In addition to its projects on laminopathy, Phlox Therapeutics aims to utilize similar RNA-based strategies to target other types of cardiomyopathy. To this end, Phlox Therapeutics is committed to developing multiple gene therapies to mitigate the negative impacts caused by genetic mutations.